Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
Avex Life Sciences Corp
Apnimed Inc
Dermavant Sciences Inc
FemmePharma Global Healthcare Inc
Karu Therapeutics Inc
Sinsin Pharmaceutical Co Ltd
TheraVida Inc
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
(atomoxetine + oxybutynin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(oxybutynin + reboxetine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(pilocarpine + tolterodine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVEX-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blarcamesine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Karu Therapeutics announces results from phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers
Jun 21, 2021: Avex Life Sciences announces AVEX2-73 (Blarcamesine) biomarker correlated with efficacy endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome
Jun 14, 2021: Avex Life Sciences reports new publication in medical jourl elucidating the mechanism of AVEX2-73 (blarcamesine) related to the treatment of Alzheimer’s Disease
Jun 08, 2021: Avex Life Sciences announces exceeding of enrollment target for the precision medicine AVEX2-73 (blarcamesine) phase 2b/3 clinical trial in patients with Alzheimer’s Disease
Jun 03, 2021: Avex Life Sciences announces Notice of allowance for U.S. patent application AVEX2-73 (blarcamesine) for the treatment of cardiac dysfunctions
May 17, 2021: New data presented at American Thoracic Society Meeting reinforces the potential of an oral drug combition therapy for the treatment of obstructive sleep apnea
Apr 12, 2021: Avex Life Sciences reports the results of review by the Independent Data Safety Monitoring Board for its phase 2/3 trials of AVEX2-73 in patients with Rett syndrome
Mar 31, 2021: Avex Life Sciences reports data review by the Independent Data Safety Monitoring board for its phase 2b/3 clinical trial of AVEX2-73 in patients with Alzheimer’s Disease
Mar 25, 2021: Apnimed closes Series B fincing to advance once-daily oral medication for Obstructive Sleep Apnea (OSA)
Mar 16, 2021: Avex Life Sciences reports AVEX2-73 (blarcamesine) featured as a disease-modifying small molecule in phase 3 clinical trials in a new publication in medical jourl titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”
Feb 24, 2021: Karu Therapeutics anounces New England Jourl of Medicine publication of data from EMERGENT-1 phase 2 trial evaluating KarXT in Schizophrenia
Jan 20, 2021: Apnimed doses first patient in obstructive sleep apnea drug trial
Jan 11, 2021: Avex Life Sciences receives Michael J. Fox Foundation grant for clinical study of AVEX2-73 (blarcamesine) in people with Parkinson’s Disease
Dec 21, 2020: Avex Life Sciences announces webir on Rett syndrome and AVEX2-73 (Blarcamesine) phase 2 data hosted by Ladenburg Thalmann & Co.
Dec 15, 2020: Avex Life Sciences announces AVEX2-73 (Blarcamesine) meets primary and secondary endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Anavex Life Sciences Corp, 2021
Pipeline by Apnimed Inc, 2021
Pipeline by Dermavant Sciences Inc, 2021
Pipeline by FemmePharma Global Healthcare Inc, 2021
Pipeline by Karuna Therapeutics Inc, 2021
Pipeline by Sinsin Pharmaceutical Co Ltd, 2021
Pipeline by TheraVida Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021